Comparative Pharmacology
Head-to-head clinical analysis: JYLAMVO versus KADCYLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JYLAMVO versus KADCYLA.
JYLAMVO vs KADCYLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent